AstraZeneca has secured four regulatory wins in a single morning, including a recommendation for EU approval of its new blood pressure pill Baxfendy.
The FTSE 100 drugmaker also won US approval for a new bladder cancer regimen built around Imfinzi, and approval on both sides of the Atlantic for Klygefa, a treatment for the rare muscle disease generalised myasthenia gravis.
Baxfendy, also known as baxdrostat, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency's advisory panel.
It is recommended for adults whose high blood pressure is not controlled by at least two existing medicines, a group of about 70 million people across Europe.
If approved, it will be the first aldosterone synthase inhibitor in the EU, a drug that blocks production of aldosterone, a hormone that pushes blood pressure up.
In the BaxHTN trial, a 2mg dose cut systolic blood pressure by 15.7 mmHg after 12 weeks, or 9.8 mmHg more than placebo.
Baxfendy is already approved in the US.
"This positive CHMP opinion for Baxfendy marks a significant step toward bringing this potential first-in-class innovation to patients in Europe," said Ruud Dobber, head of AstraZeneca's biopharmaceuticals business.
In the US, the Food and Drug Administration (FDA) approved Imfinzi alongside enfortumab vedotin for muscle-invasive bladder cancer patients who cannot have, or have refused, cisplatin chemotherapy.
Patients receive both drugs before surgery to remove the bladder, followed by Imfinzi alone afterwards.
In the VOLGA trial, the regimen cut the risk of the disease progressing or returning by 49% and the risk of death by 42% compared with surgery alone or with approved follow-up treatment.
Severe side effects were more common, affecting 64% of patients on the combination against 44% in the comparison group.
Around 16,000 patients will be treated for the disease in the US this year, and this is Imfinzi's third bladder cancer approval in two years.
Klygefa, developed by AstraZeneca's rare disease unit Alexion, was approved by both the FDA and the European Commission for adults with generalised myasthenia gravis, an autoimmune condition that causes severe muscle weakness.
It is the first approved dual-binding nanobody C5 inhibitor, a small antibody fragment that blocks part of the immune system from attacking the junction between nerves and muscles.
Patients can inject it themselves once a week using an autoinjector.
In the PREVAIL trial, it improved patients' ability to carry out daily activities compared with placebo, with benefits seen from the first week.
About 81,000 people in the US and 66,000 in Europe's five biggest markets have the form of the disease the drug targets.
"The approval of Klygefa in Europe marks an important milestone for the gMG community," said Alexion chief executive Marc Dunoyer.
Klygefa is already approved in Japan, with applications under review in China.